TFS seminar Secrets to Biotech Success brings together industry stakeholders recognizing a strategic partnership as the foundation of the biotech success.
On September 19th, TFS hosted a seminar in Medicon Village starting a much needed discussion about the changes impacting the biopharmaceutical industry. Representatives from the biotech, academic and investor community came together to share their unique business perspective.
A significant and increasing portion of biopharmaceutical R&D worldwide is currently created by small and midsize biotechnology, medical device and medical technology companies. On the other hand, the biotechnology industry is also facing challenges. It’s no longer enough to create products that are innovative, safe and effective. Janos Filakovský, TFS CEO comments “The secret of the success depends on the understanding of the drug discovery process, the ability to evaluate risk factors and the capability to demonstrate commercial value early on.” Pursuing a value-based R&D strategy allows using data generated in the research process to show how new products will not only be clinically beneficial but will also meet the needs of patients and investors. Early engagement as well as a lasting partnership between CRO and customers, was highlighted as one of the essential items for the successful product development process and delivery.
TFS has been growing strategically to provide customers with the expertise and services needed throughout their clinical development journey. Per Magnusson, Chairman of TFS Board, recognizes the role TFS plays in the industry “TFS has been successfully following the strategy to strengthen its position and initiatives such the recent seminar show our commitment to become partners and help our customers navigate the complex landscape of biopharma.”
Secrets to Biotech Success is the first in the series of events to be organized by TFS, global clinical research provider.
For further information please contact:
Director Corporate Communications and Enterprise Digital
Phone: +48 787 913 074
TFS was founded in 1996 and has grown to become the leading global mid-size clinical CRO focusing on small and mid-size life science customers. TFS employs more than 700 professionals throughout 21 countries and currently delivers clinical research services in more than 40 countries. We provide end-to-end solutions or flexible single services. Our partnering approach with customers is based on our four business principles – commitment, flexibility, value creation and global reach. Our core therapeutic specialties are Oncology, Immunology, Dermatology, Ophthalmology, CNS, Cardiology and Endocrinology.
Detailed information about TFS, and its business offerings can be obtained through www.tfscro.com